Abstract
The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life. However, the use of LABAs has raised safety concerns, such as their potential to provoke severe asthma exacerbations (SAEs) and death. This systematic review of major findings discusses the safety controversy surrounding LABA therapy and provides background for the U.S. Food and Drug Administrations warnings concerning LABA use. Findings from large clinical trials and several meta-analyses are described and compared in terms of their implications for the safety of LABAs. Monotherapy LABA therapy in the treatment of asthma remains controversial and is not recommended by the most recent asthma management guidelines. Despite the existence of numerous published studies, we conclude that more well-designed research on this topic --- to determine whether LABAs are associated with SAEs, such as asthma-related hospitalizations, intubations, and emergency room visits, or death --- is required. Particularly needed is research that makes use of large, secondary longitudinal databases.
Keywords: Long-acting beta agonists (LABAs), asthma, SMART trial, safety controversy, African Americans, pediatric LABA use
Current Drug Safety
Title: Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma
Volume: 5 Issue: 3
Author(s): Boyang Bian, Christina M.L. Kelton, Patricia R. Wigle and Jeff J. Guo
Affiliation:
Keywords: Long-acting beta agonists (LABAs), asthma, SMART trial, safety controversy, African Americans, pediatric LABA use
Abstract: The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life. However, the use of LABAs has raised safety concerns, such as their potential to provoke severe asthma exacerbations (SAEs) and death. This systematic review of major findings discusses the safety controversy surrounding LABA therapy and provides background for the U.S. Food and Drug Administrations warnings concerning LABA use. Findings from large clinical trials and several meta-analyses are described and compared in terms of their implications for the safety of LABAs. Monotherapy LABA therapy in the treatment of asthma remains controversial and is not recommended by the most recent asthma management guidelines. Despite the existence of numerous published studies, we conclude that more well-designed research on this topic --- to determine whether LABAs are associated with SAEs, such as asthma-related hospitalizations, intubations, and emergency room visits, or death --- is required. Particularly needed is research that makes use of large, secondary longitudinal databases.
Export Options
About this article
Cite this article as:
Bian Boyang, M.L. Kelton Christina, R. Wigle Patricia and J. Guo Jeff, Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma, Current Drug Safety 2010; 5 (3) . https://dx.doi.org/10.2174/157488610791698316
DOI https://dx.doi.org/10.2174/157488610791698316 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
T Cell Homeostasis in Centenarians: From the Thymus to the Periphery
Current Pharmaceutical Design Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety Breaking the Skin Barrier: Achievements and Future Directions
Current Pharmaceutical Design Asthma-COPD Overlap (ACO) among Adult-onset Asthma Patients
Current Respiratory Medicine Reviews Bronchoscopy in Children for Research with Questionable Indications: An Overview of Russian Patents and Publications
Recent Patents on Drug Delivery & Formulation Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters Recent Advances in Colon Drug Delivery Technology
Drug Delivery Letters Subtype Selectivity in Phosphodiesterase 4 (PDE4): A Bottleneck in Rational Drug Design
Current Pharmaceutical Design The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Bipolar Affective Disorder in Young People: A Review
Adolescent Psychiatry Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Macrolides as Immunomodulatory Agents: Review and Future Directions
Medicinal Chemistry Reviews - Online (Discontinued) New Approaches for the Treatment of Allergic Conditions
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Patents on the Treatment of Type 1 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Carbohydrates in Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Signal Transducer and Activator of Transcription 5 (STAT5), a Crucial Regulator of Immune and Cancer Cells
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Protein Profile of Fibroblasts: The Role of Proteomics
Current Proteomics Allergy in Pediatric Age: An Update
Current Pediatric Reviews Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry